LivaNova (LIVN) Total Current Liabilities (2015 - 2026)
LivaNova (LIVN) reported Total Current Liabilities of $762.5 million for Q1 2026, up 2.82% on a YoY basis from $741.6 million in Q1 2025, and down 5.64% sequentially from $808.1 million in Q4 2025.
LivaNova (LIVN) Total Current Liabilities (2015 - 2026) Analysis & Trends
LivaNova (LIVN) has 12 years of Total Current Liabilities data on file, last reported at $762.5 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 2.82% year-over-year to $762.5 million; the trailing twelve-month figure through Mar 2026 stood at $762.5 million (up 2.82% YoY), and the FY2025 full-year result was $808.1 million, up 106.08% from the prior year.
- Total Current Liabilities eased to $762.5 million in Q1 2026, from $808.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $827.6 million in Q3 2025 to a low of $263.9 million in Q2 2022.
- A 5-year average of $453.3 million and a median of $324.4 million in 2024 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities plunged 62.42% in 2022 and jumped 172.98% in 2025, its largest moves.
- Tracing LIVN's Total Current Liabilities over 5 years: stood at $297.4 million in 2022, then grew by 12.64% to $335.0 million in 2023, then rose by 17.06% to $392.1 million in 2024, then surged by 106.08% to $808.1 million in 2025, then dropped by 5.64% to $762.5 million in 2026.
- Business Quant data shows LIVN's Total Current Liabilities at $762.5 million in Q1 2026, $808.1 million in Q4 2025, and $827.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.26 Bn | 176.96 Bn | 6.27 Bn | 18.38 Bn |
| 2 | Stryker | 128.82 Bn | 125.94 Bn | 3.81 Bn | 6.32 Bn |
| 3 | Medtronic | 108.86 Bn | 99.64 Bn | 6.41 Bn | 11.66 Bn |
| 4 | Boston Scientific | 68.54 Bn | 67.09 Bn | 3.61 Bn | 4.57 Bn |
| 5 | Edwards Lifesciences | 47.53 Bn | 43.86 Bn | 1.29 Bn | 1.41 Bn |
| 6 | GE HealthCare Technologies | 28.45 Bn | 26.17 Bn | 1.98 Bn | 8.53 Bn |
| 7 | Dexcom | 28.43 Bn | 27.31 Bn | 750.30 Mn | 2.22 Bn |
| 8 | Smith & Nephew | 26.96 Bn | 26.39 Bn | - | 1.60 Bn |
| 9 | Koninklijke Philips | 25.53 Bn | 22.41 Bn | 2.07 Bn | 8.70 Bn |
| 10 | LivaNova | 4.37 Bn | 3.83 Bn | 243.75 Mn | 762.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 762.48 Mn |
| Dec 31, 2025 | 808.07 Mn |
| Sep 30, 2025 | 827.59 Mn |
| Jun 30, 2025 | 827.10 Mn |
| Mar 31, 2025 | 741.57 Mn |
| Dec 31, 2024 | 392.13 Mn |
| Sep 30, 2024 | 324.40 Mn |
| Jun 30, 2024 | 302.99 Mn |
| Mar 31, 2024 | 327.77 Mn |
| Dec 31, 2023 | 334.98 Mn |
| Sep 30, 2023 | 295.40 Mn |
| Jun 30, 2023 | 288.16 Mn |
| Mar 31, 2023 | 316.13 Mn |
| Dec 31, 2022 | 297.40 Mn |
| Sep 30, 2022 | 288.02 Mn |
| Jun 30, 2022 | 263.89 Mn |
| Mar 31, 2022 | 307.91 Mn |
| Dec 31, 2021 | 696.97 Mn |
| Sep 30, 2021 | 658.47 Mn |
| Jun 30, 2021 | 702.25 Mn |